Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial

被引:403
作者
Dans, Antonio L. [1 ]
Connolly, Stuart J. [2 ]
Wallentin, Lars [3 ,4 ]
Yang, Sean [2 ]
Nakamya, Juliet [2 ]
Brueckmann, Martina [5 ]
Ezekowitz, Michael [6 ,7 ]
Oldgren, Jonas [3 ,4 ]
Eikelboom, John W. [2 ]
Reilly, Paul A. [8 ]
Yusuf, Salim [2 ]
机构
[1] Univ Philippines, Coll Med, Manila 1000, Philippines
[2] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8S 4L8, Canada
[3] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[4] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
[5] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[6] Jefferson Med Coll, Wynnewood, PA USA
[7] Cardiovasc Res Fdn, New York, NY USA
[8] Boehringer Ingelheim Pharma Inc, Ingelheim, Germany
关键词
antiplatelets; aspirin; atrial fibrillation; clopidogrel; dabigatran; embolism; hemorrhage; oral anticoagulants; stroke; warfarin; ACUTE CORONARY SYNDROMES; METAANALYSIS; ASPIRIN; COMBINATION; APIXABAN; BENEFITS; RISKS;
D O I
10.1161/CIRCULATIONAHA.112.115386
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 mg BID was noninferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. In this subgroup analysis, we assess the efficacy and safety of dabigatran in patients who did and did not receive concomitant antiplatelets. Methods and Results-All comparisons used a Cox proportional hazards model with adjustments made for risk factors for bleeding. A time-dependent analysis was performed when comparing patients with concomitant antiplatelets with those without. Of 18 113 patients, 6952 (38.4%) received concomitant aspirin or clopidogrel at some time during the study. Dabigatran etexilate 110 mg BID was noninferior to warfarin in reducing stroke and systemic embolism, whether patients received antiplatelets (hazard ratio [HR], 0.93; 95% confidence interval [95% CI], 0.70-1.25) or not (HR, 0.87; 95% CI, 0.66-1.15; interaction P=0.738). There were fewer major bleeds than warfarin in both subgroups (HR, 0.82; 95% CI, 0.67-1.00 for patients who used antiplatelets; HR, 0.79; 95% CI, 0.64-0.96 for patients who did not; interaction P=0.794). Dabigatran etexilate 150 mg BID reduced the primary outcome of stroke and systemic embolism in comparison with warfarin. This effect seemed attenuated among patients who used antiplatelets (HR, 0.80; 95% CI, 0.59-1.08) in comparison with those who did not (HR, 0.52; 95% CI, 0.38-0.72; P for interaction=0.058). Major bleeding was similar to warfarin regardless of antiplatelet use (HR, 0.93; 95% CI, 0.76-1.12 for patients who used antiplatelets; HR, 0.94; 95% CI, 0.78-1.15 for patients who did not; P for interaction=0.875). In the time-dependent analysis, concomitant use of a single antiplatelet seemed to increase the risk of major bleeding (HR, 1.60; 95% CI, 1.42-1.82). Dual antiplatelet seemed to increased this even more (HR, 2.31; 95% CI, 1.79-2.98). The absolute risks were lowest on dabigatran etexilate 110 mg BID in comparison with dabigatran etexilate 150 mg BID or warfarin. Conclusions-Concomitant antiplatelet drugs appeared to increase the risk for major bleeding in RE-LY without affecting the advantages of dabigatran over warfarin. Choosing between dabigatran etexilate 110 mg BID and dabigatran etexilate 150 mg BID requires a careful assessment of characteristics that influence the balance between benefit and harm.
引用
收藏
页码:634 / 640
页数:7
相关论文
共 14 条
[1]   Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome [J].
Alexander, John H. ;
Lopes, Renato D. ;
James, Stefan ;
Kilaru, Rakhi ;
He, Yaohua ;
Mohan, Puneet ;
Bhatt, Deepak L. ;
Goodman, Shaun ;
Verheugt, Freek W. ;
Flather, Marcus ;
Huber, Kurt ;
Liaw, Danny ;
Husted, Steen E. ;
Lopez-Sendon, Jose ;
De Caterina, Raffaele ;
Jansky, Petr ;
Darius, Harald ;
Vinereanu, Dragos ;
Cornel, Jan H. ;
Cools, Frank ;
Atar, Dan ;
Luis Leiva-Pons, Jose ;
Keltai, Matyas ;
Ogawa, Hisao ;
Pais, Prem ;
Parkhomenko, Alexander ;
Ruzyllo, Witold ;
Diaz, Rafael ;
White, Harvey ;
Ruda, Mikhail ;
Geraldes, Margarida ;
Lawrence, Jack ;
Harrington, Robert A. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) :699-708
[2]   Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients [J].
Andreotti, F ;
Testa, L ;
Biondi-Zoccai, GGL ;
Crea, F .
EUROPEAN HEART JOURNAL, 2006, 27 (05) :519-526
[3]   Meta-Analysis of Multiple Primary Prevention Trials of Cardiovascular Events Using Aspirin [J].
Bartolucci, Alfred A. ;
Tendera, Michal ;
Howard, George .
AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (12) :1796-1801
[4]   Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[5]   Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease - A meta-analysis of randomized trials [J].
Dentali, Francesco ;
Douketis, James D. ;
Lim, Wendy ;
Crowther, Mark .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (02) :117-124
[6]   Combination warfarin-ASA therapy: Which patients should receive it, which patients should not, and why? [J].
Douketis, James D. .
THROMBOSIS RESEARCH, 2011, 127 (06) :513-517
[7]   Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials [J].
Flaker, Greg C. ;
Gruber, Michael ;
Connolly, Stuart J. ;
Goldman, Steven ;
Chaparro, Sandra ;
Vahanian, Alec ;
Halinen, Matti O. ;
Horrow, Jay ;
Halperin, Jonathan L. .
AMERICAN HEART JOURNAL, 2006, 152 (05) :967-973
[8]   Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical Revascularization for non-ST-elevation acute coronary syndrome - The Clopidogrel in Unstable Angina to prevent Recurrent Ischemic Events (CURE) trial [J].
Fox, KAA ;
Mehta, SR ;
Peters, R ;
Zhao, F ;
Lakkis, N ;
Gersh, BJ ;
Yusuf, S .
CIRCULATION, 2004, 110 (10) :1202-1208
[9]   Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation [J].
Gao, Fei ;
Zhou, Yu Jie ;
Wang, Zhi Jian ;
Yang, Shi Wei ;
Nie, Bin ;
Liu, Xiao Li ;
Jia, De An ;
Yan, Zhen Xian .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 148 (01) :96-101
[10]   Apixaban versus Warfarin in Patients with Atrial Fibrillation [J].
Granger, Christopher B. ;
Alexander, John H. ;
McMurray, John J. V. ;
Lopes, Renato D. ;
Hylek, Elaine M. ;
Hanna, Michael ;
Al-Khalidi, Hussein R. ;
Ansell, Jack ;
Atar, Dan ;
Avezum, Alvaro ;
Cecilia Bahit, M. ;
Diaz, Rafael ;
Easton, J. Donald ;
Ezekowitz, Justin A. ;
Flaker, Greg ;
Garcia, David ;
Geraldes, Margarida ;
Gersh, Bernard J. ;
Golitsyn, Sergey ;
Goto, Shinya ;
Hermosillo, Antonio G. ;
Hohnloser, Stefan H. ;
Horowitz, John ;
Mohan, Puneet ;
Jansky, Petr ;
Lewis, Basil S. ;
Luis Lopez-Sendon, Jose ;
Pais, Prem ;
Parkhomenko, Alexander ;
Verheugt, Freek W. A. ;
Zhu, Jun ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :981-992